БИС Джоанна (US),ИГО Давид Х. (US),ХО Берт (US),ШАХ Девен (US)
申请号：
RU2014104991/04
公开号：
RU2014104991A
申请日:
2012.07.20
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. The crystalline form of the sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-hydroxy-pyridin-4-carbonyl) phenyl] benzene sulfonamide, in which the crystalline form is characterized by X-ray powder diffraction (XRPD) structure including diffraction angles measured using CuK radiation at approximately 4.5, 9.0, 13.6, 13.9, 15.8, 19.9, 20.4 and 28.0 ° 2θ. 2. The crystalline form of the sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-hydroxy-pyridin-4-carbonyl) phenyl] benzene sulfonamide, in which the crystalline form is characterized by an X-ray powder diffraction structure essentially according to FIG. 1.3. The crystalline form of the 4-tert-butyl-N- [4-chloro-2- (1-hydroxy-pyridin-4-carbonyl) phenyl] benzene sulfonamide sodium salt in which the crystalline form provides a Raman spectrum containing peaks at about 688, 743, 803, 1125, 1154, 1162, 1286, 1587, 1596, 1656 and 1672 cm. 4. The crystalline form of the sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-hydroxy-pyridin-4-carbonyl) phenyl] benzene sulfonamide, in which the crystalline form provides the Raman spectrum essentially in accordance with FIG. 3.5. A pharmaceutical composition comprising a crystalline form according to any one of claims. 1-4 and a pharmaceutically acceptable carrier. 6. A method for producing a pharmaceutical composition comprising mixing a crystalline form according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier. The crystalline form of the sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-hydroxy-pyridin-4-carbonyl) phenyl] benzene sulfonamide, in which the crystalline form is characterized by an X-ray powder diffraction structure including diffraction angles at measurement using CuK radiation at approximately 4.5, 9.1, 13.6, 13.9, 181. Кристаллическая форма натриевой соли 4-трет-бутил-N-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида, в которой кристаллическая форма характеризуется рентгеновской порошковой дифракционной (XRPD) структурой, включающей
